CASMED Announces Grant of Patent in Japan for FORE-SIGHT Technology
- Patent Strengthens CASMED's Worldwide IP Portfolio -
Branford, Conn. - April 13, 2010 - CAS Medical Systems, Inc. (NASDAQ: CASM) today announced that that the Japanese Patent Office has granted a new patent for the Company's LASER-SIGHT® technology used in the FORE-SIGHT® Oximeter.
The newly granted patent (JP 4,465,271), entitled Method for spectrophotometric blood oxygenation monitoring, includes 28 claims broadly covering methods for non-invasively determining biological tissue oxygenation in general, and for non-invasive methods utilizing near-infrared spectroscopy (NIRS) techniques in particular, including:
- a method for non-invasively determining the absolute oxygen saturation value within biological tissue;
- a method that provides calibration means to account for energy losses due to scattering as well as other background absorption from biological compounds; and
- a method that can non-invasively determine oxygen saturation within tissue at certain depth that limits the influence from the superficial tissues.
"We are very pleased with the grant of this first FORE-SIGHT related patent in Japan, which further extends CASMED's leadership on intellectual property for absolute oximetry measurements," said Andrew Kersey, President and Chief Executive Officer of CASMED. "Japan is known for having a rigorous approval process for patents, and this will offer us protection on our invention and intellectual property in this country.
"The patent reflects many years of research and development focused on bringing to market a non-invasive, commercially viable technology that allows clinicians to monitor absolute levels of oxygen saturation in the brain and other body tissues. Our goal is to continue to pursue the issuance of patents to enable us to maximize the value of the innovative technology used in this compelling device."
About CASMED® - Monitoring What's Vital
CAS Medical Systems, Inc. is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter is the only cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for all patients, regardless of age or weight. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition.The Company's product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Cerebral Oximeter; the bedside patient monitoring line of vital signs monitoring products, proprietary non-invasive blood pressure measurement technology, and supplies and service including blood pressure cuffs and products for neonatal intensive care. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates.
For further information regarding CAS Medical Systems, Inc., visit the Company's website at www.casmed.com.
Company Contacts
CAS Medical Systems, Inc.
Susan Carron
Director of Corporate Communications
203-488-6056
ir@casmed.com
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the result of on-going litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders and competitors and other risks detailed in the Company's Form 10-K for the year ended December 31, 2009 and other subsequent Securities and Exchange Commission filings.
Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.
